Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Needs ‘More Streamlined’ REMS Enforcement Authority, Inspector General Says

Executive Summary

Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.

You may also be interested in...



User Fee Renewal Negotiations Beginning This Week

Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.

US FDA Hiring Strategy Shifts Focus From ‘Vacancies’ To ‘Net Gains’

As outside report urges increased planning and culture changes,  FDA OTS Director Keller says recruitment will stop ‘order taking’ and move to ‘forecasting the hiring needs of each of the centers.’

Opioid Labeling Instructions On Naloxone Are Compromise In Co-Prescribing Debate

US FDA says opioid and opioid use disorder treatment labels should suggest providers discuss naloxone availability with patients and caregivers and consider co-prescribing to patients at high-risk of overdose, but it does not mandate co-prescribing, the most aggressive (and costly) option that had been considered.

Related Content

Topics

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel